Topic: small cell lung cancer
With the priority review, Imfinzi is now looking at a decision for use in frontline small cell lung cancer by the first quarter of 2020.
When AbbVie splashed $5.8 billion upfront and reserved another $4 billion in milestones for Stemcentrx in 2016, the primary focus was Rova-T.
Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.
Roche’s Tecentriq is the only I-O drug approved in small cell lung cancer. But it may soon have to make some room for AstraZeneca’s Imfinzi.
Roche’s Tecentriq is on a roll in Europe. After picking up a green light in breast cancer last week, it's now snagged a pair of go-aheads in lung cancer.
AstraZeneca has some good news to report in lung cancer. But it's from the small cell lung cancer field where Roche’s Tecentriq is a step ahead.
As Opdivo's small cell lung cancer nod looks shaky after two failed trials, Keytruda has chalked up an approval in the third-line setting.
Merck is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case.
Just a week after Roche’s Tecentriq became the first FDA-approved I-O agent in breast cancer, the drug has clinched another first-in-class nod.
The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.